{
    "clinical_study": {
        "@rank": "30367", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic\n      breast cancer at 2 dose levels."
        }, 
        "brief_title": "This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "November 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Breast Neoplasms", 
            "Metastases, Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological and/or cytological confirmation of metastatic breast cancer which is\n             refractory to anthracycline, taxane, with or without capecitabine therapies;\n\n          -  WHO performance status 0, 1 or 2 on the day of registration;\n\n          -  Females, aged >= 18 years;\n\n          -  No Gastrointestinal pathology which could affect the bioavailability of ZD6474.\n\n        Exclusion Criteria:\n\n          -  Any evidence of severe or uncontrolled systemic diseases including known cases of\n             Hepatitis B or C or human immunodeficiency virus (HIV).\n\n          -  Significant cardiac event (including symptomatic heart failure or unstable angina)\n             within 3 months of entry or any cardiac disease that in the opinion of the\n             investigator increases risk for ventricular arrhythmia;\n\n          -  History of clinically significant cardiac arrhythmia (multifocal PVCs, bigeminy,\n             trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTC\n             grade 3) or asymptomatic sustained ventricular tachycardia;\n\n          -  Chronic atrial fibrillation;\n\n          -  Previous history of QT / QTc prolongation with other medication;\n\n          -  Congenital long QT syndrome;\n\n          -  Systemic anti-cancer therapy or other investigational agent within the last 4 weeks\n             (6 weeks for nitrosoureas, mitomycin C, or suramin);\n\n          -  Currently receiving drugs with known significant 3A4 inhibitory (ie, ketoconazole,\n             itraconazole, troleandomycin, erythromycin, diltiazem, verapamil) or stimulatory (ie,\n             phenytoin, carbamazepine, barbiturates, rifampicin) effects;\n\n          -  Currently receiving therapeutic doses of warfarin (Coumadin?)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "44", 
        "firstreceived_date": "May 2, 2002", 
        "id_info": {
            "nct_id": "NCT00034918", 
            "org_study_id": "6474IL/0002"
        }, 
        "intervention": {
            "intervention_name": "ZD6474", 
            "intervention_type": "Drug"
        }, 
        "keyword": "Metastatic breast cancer", 
        "lastchanged_date": "January 3, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "official_title": "An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).", 
        "overall_official": {
            "affiliation": "AstraZeneca", 
            "last_name": "ZD6474 Medical Science Director, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034918"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "Research Site": "41.388 2.17"
    }
}